BANK VONTOBEL/CALL/NOVO NORDISK ADR B/210/0.1/17.01.25

BANK VONTOBEL/CALL/NOVO NORDISK ADR B/210/0.1/17.01.25 Share Price

DE000VD10NR1

Real-time Boerse Frankfurt Warrants 05:33:18 01/07/2024 pm IST
0.152 ^EUR	-3.18%

1 month	+58.59%
3 months	-32.91%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart NOVO NORDISK A/S

Chart BANK VONTOBEL/CALL/NOVO NORDISK ADR B/210/0.1/17.01.25

Latest news about NOVO NORDISK A/S

Thinking about trading options or stock in Tesla, Microsoft, Novo Nordisk, Intel, or Solaredge Technologies?	07/02	PR
Thinking about buying stock in NKGen Biotech, Novo Nordisk, SoundHound AI, Safety Shot, or Energy Fuels?	01/02	PR
Thinking about buying stock in Estrella Immunopharma, Novo Nordisk, C4 Therapeutics, Plug Power, or LQR House?	17/01	PR
Thinking about buying stock in Transphorm Technology, Stronghold Digital Mining, Broadcom, Novo Nordisk, or Datadog?	11/01	PR

More news

Quotes 5-day view

Date	Price	Change
01/24/01	0.152	-3.18%
28/24/28	0.157	-3.09%
27/24/27	0.162	-2.41%
26/24/26	0.166	-17.00%
25/24/25	0.2	+47.06%

Real-time Boerse Frankfurt Warrants

Last update July 01, 2024 at 05:33 pm IST

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	NOVO NORDISK A/S
Issuer	Vontobel
WKN	VD10NR
ISIN	DE000VD10NR1
Date issued	12/03/2024
Strike	210 $
Maturity	17/01/2025 (200 Days)
Parity	10 : 1
Emission price	0.25 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	0.39 €
Lowest since issue	0.076 €
Delta	0.11x
Omega	8.716
Premium	48.37x
Gearing	79.92x
Moneyness	0.6797
Difference Strike	65.62 $
Difference Strike %	+31.25%
Spread	0.03 €
Spread %	16.57%
Theoretical value	0.1650
Implied Volatility	34.85 %
Total Loss Probability	93.11 %
Intrinsic value	0.000000
Present value	0.1650
Break even	211.77 €
Theta	-0.01x
Vega	0.02x
Rho	0.01x

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).

Sector

More about the company